Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Loxapine→

Loxapine Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
1977-10-2
Molecular formula
C18H18ClN3O
Molecular weight
327.8 g/mol
Drug class
Dibenzoxazepine antipsychoticdopamine and serotonin receptor antagonist
Mechanism of action
Acts as an antagonist at central dopamine and serotonin receptors, including D2 and 5-HT2A receptors. The precise mechanism responsible for clinical antipsychotic effects is not fully established.
Indications / reported uses
  • Treatment of schizophrenia with oral formulations.
  • Acute treatment of agitation associated with schizophrenia or bipolar I disorder with the inhaled formulation, where authorised.

Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2cf83a3e-d76d-2a1f-e063-6294a90aa6bc · https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022549s000lbl.pdf

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Loxapine Environmental Risk Assessment (ERA) (the Loxapine ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.